Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study | Zendy

Adam Corken | Zendy; Jerry Ware | Zendy; Junqiang Dai | Zendy; John M. Arthur | Zendy; Susan S. Smyth | Zendy; Clayton Davis | Zendy; Juan Liu | Zendy; Terry Harville | Zendy; Milind A. Phadnis | Zendy; Jawahar L. Mehta | Zendy; Yasir Rahmatallah | Zendy; Nishank Jain | Zendy

Open Access

Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study

Author(s) -

Adam Corken,

Jerry Ware,

Junqiang Dai,

John M. Arthur,

Susan S. Smyth,

Clayton Davis,

Juan Liu,

Terry Harville,

Milind A. Phadnis,

Jawahar L. Mehta,

Yasir Rahmatallah,

Nishank Jain

Publication year - 2022

Publication title -

kidney360

Language(s) - English

Resource type - Journals

ISSN - 2641-7650

DOI - 10.34067/kid.0005532022

Subject(s) - platelet , medicine , kidney disease , platelet activation , aspirin , renal function , inflammation , mean platelet volume , immunology , endocrinology

Chronic kidney disease (CKD) is characterized by dysregulated inflammation that worsens with CKD severity. The role of platelets in modulating inflammation in stage 4 or 5 CKD remains unexplored. We investigated whether there are changes in platelet-derived thromboinflammatory markers in CKD with dual antiplatelet therapy (DAPT; aspirin 81 mg/d plus P2Y12 inhibitor).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research